22 May 2013
Keywords: GlaxoSmithKline, Theravance, Umeclidinium, Vilanterol, COPD, UMED/VI
Article | 02 July 2012
UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) this morning announced the results of four pivotal ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 July 2012
1 July 2012
© 2013 thepharmaletter.com